Kangyuan Pharmaceutical Co., Ltd. increases the production of plant extracts

Kangyuan Pharmaceutical Co., Ltd announced on January 18, 2013 that the company plans to issue 2019.07 million shares to Jiangsu Kangyuan group, a major shareholder, and its concerted actor, huitianfu Kangyuan asset management plan The total amount of raised funds is 360 million yuan, which is mainly used to expand the company's plant extract capacity According to the plan, 324 million yuan of the raised funds will be used for the production project of 1500 tons of plant extract series products Plant extract is the necessary raw material for the production of the company's main products, such as Reduning, ginkgo diterpenoid lactone and other traditional Chinese medicine injections Through this non-public offering, the production scale of plant extracts of Kangyuan pharmaceutical will be expanded, the market share will be increased, the market competitiveness will be enhanced, and the profit level of Kangyuan pharmaceutical will be improved In mid November 2012, Kangyuan pharmaceutical announced that its heavy new drug ginkgolide, which has been researched and developed for more than 10 years, has obtained the production approval document and can be put on the market as soon as around the middle of 2013 It is expected to become an important injection product of Kangyuan pharmaceutical industry after being put on the market At present, only Chengdu Baiyu has obtained the production batch number of the same type of drugs in the market, and the market competition is limited The market scale of Ginkgo biloba products is close to 5 billion yuan, and the annual sales volume of Ginkgo biloba injection is about 300 million pieces In the face of such a huge market demand, the company's profit growth space is considerable However, shortly after Kangyuan pharmaceutical obtained the approval of ginkgolide injection, a research report of Guoxin Securities pointed out that there are many enterprises submitting for approval for this kind of products in the future, with fierce competition, or it is difficult to reach the sales scale predicted by the market In addition, according to relevant persons of Kangyuan pharmaceutical industry, the website of the State Food and Drug Administration shows that it is to be certified, and it is also possible to get an approval document of not approved production There is a risk of uncertainty in the batch number of the new drug.